ANAB

Imsidolimab

Generalized Pustular Psoriasis (GPP)

FDA end-of-Phase 2 meeting with FDA

Exp Date

Q4 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Imsidolimb for Generalized Pustular Psoriasis (GPP) End-of-phase 2 meeting with FDA

  • Clinical Trial (NCT03619902) A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis (GPP)


WHAT IS THE NEXT CATALYST EVENT?

  •  End-of-phase 2 meeting with FDA


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020 


PRIOR DATA/EVENTS

PRESS RELEASES

Updated by MV

imsidolimab, GPP, generalized pustular psoriasis, ANAB, skin disorder, skin disease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon